PURPOSE: Early breast cancer presents with a remarkable heterogeneity of outcomes. Undetected, microscopic lymph node tumor deposits may account for a significant fraction of this prognostic diversity. Thus, we systematically evaluated the presence of lymph node tumor cell deposits<or=0.2 mm in diameter [pN0(i+), nanometastases] and analyzed their prognostic effect. EXPERIMENTAL DESIGN: Single-institution, consecutive patients with 8 years of median follow-up (n=702) were studied. To maximize chances of detecting micrometastases and nanometastases, whole-axilla dissections were analyzed. pN0 cases (n=377) were systematically reevaluated by lymph node (n=6676) step-sectioning and anticytokeratin immunohistochemical analysis. The risk of first adverse events and of distant relapse of bona fide pN0 patients was compared with that of pN0(i+), pN1mi, and pN1 cases. RESULTS: Minimal lymph node deposits were revealed in 13% of pN0 patients. The hazard ratio for all adverse events of pN0(i+) versus pN0(i-) was 2.51 (P=0.00019). Hazards of pN1mi and pN0(i+) cases were not significantly different. A multivariate Cox model showed a hazard ratio of 2.16 for grouped pN0(i+)/pN1mi versus pN0(i-) (P=0.0005). Crude cumulative incidence curves for metastatic relapse were also significantly different (Gray's test chi2=5.54, P=0.019). CONCLUSION: Nanometastases are a strong risk factor for disease-free survival and for metastatic relapse. These findings support the inclusion of procedures for nanometastasis detection in tumor-node-metastasis staging.
PURPOSE: Early breast cancer presents with a remarkable heterogeneity of outcomes. Undetected, microscopic lymph node tumor deposits may account for a significant fraction of this prognostic diversity. Thus, we systematically evaluated the presence of lymph node tumor cell deposits<or=0.2 mm in diameter [pN0(i+), nanometastases] and analyzed their prognostic effect. EXPERIMENTAL DESIGN: Single-institution, consecutive patients with 8 years of median follow-up (n=702) were studied. To maximize chances of detecting micrometastases and nanometastases, whole-axilla dissections were analyzed. pN0 cases (n=377) were systematically reevaluated by lymph node (n=6676) step-sectioning and anticytokeratin immunohistochemical analysis. The risk of first adverse events and of distant relapse of bona fide pN0 patients was compared with that of pN0(i+), pN1mi, and pN1 cases. RESULTS: Minimal lymph node deposits were revealed in 13% of pN0 patients. The hazard ratio for all adverse events of pN0(i+) versus pN0(i-) was 2.51 (P=0.00019). Hazards of pN1mi and pN0(i+) cases were not significantly different. A multivariate Cox model showed a hazard ratio of 2.16 for grouped pN0(i+)/pN1mi versus pN0(i-) (P=0.0005). Crude cumulative incidence curves for metastatic relapse were also significantly different (Gray's test chi2=5.54, P=0.019). CONCLUSION: Nanometastases are a strong risk factor for disease-free survival and for metastatic relapse. These findings support the inclusion of procedures for nanometastasis detection in tumor-node-metastasis staging.
Authors: Shuang Cai; Sharadvi Thati; Taryn R Bagby; Hassam-Mustafa Diab; Neal M Davies; Mark S Cohen; M Laird Forrest Journal: J Control Release Date: 2010-04-18 Impact factor: 9.776
Authors: Roberto Plebani; Gavin R Oliver; Marco Trerotola; Emanuela Guerra; Pamela Cantanelli; Luana Apicella; Andrew Emerson; Alessandro Albiero; Paul D Harkin; Richard D Kennedy; Saverio Alberti Journal: Neoplasia Date: 2012-11 Impact factor: 5.715
Authors: Elizabeth A Mittendorf; Aysegul A Sahin; Susan L Tucker; Funda Meric-Bernstam; Min Yi; Khazi M Nayeemuddin; Gildy V Babiera; Merrick I Ross; Barry W Feig; Henry M Kuerer; Kelly K Hunt Journal: Ann Surg Oncol Date: 2008-09-25 Impact factor: 5.344
Authors: Eva M Sevick-Muraca; Ruchi Sharma; John C Rasmussen; Milton V Marshall; Juliet A Wendt; Hoang Q Pham; Elizabeth Bonefas; Jessica P Houston; Lakshmi Sampath; Kristen E Adams; Darlene Kay Blanchard; Ronald E Fisher; Stephen B Chiang; Richard Elledge; Michel E Mawad Journal: Radiology Date: 2008-01-25 Impact factor: 11.105
Authors: Yan Li; Anatoliy A Melnikov; Victor Levenson; Emanuela Guerra; Pasquale Simeone; Saverio Alberti; Youping Deng Journal: BMC Cancer Date: 2015-05-19 Impact factor: 4.430